Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Nuclear Medicine

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 17 articles:
HTML format

Single Articles

    May 2021
  1. JANI AB, Schreibmann E, Goyal S, Halkar R, et al
    (18)F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00581.
    PubMed     Abstract available

    March 2021
  2. STEINBERG J, Thomas A, Iravani A
    (18)Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
    Lancet. 2021 Mar 8. pii: S0140-6736(21)00464.

    February 2021
  3. HOPE TA, Calais J
    PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer.
    Lancet. 2021 Feb 11. pii: S0140-6736(21)00349.

    September 2020
  4. LEVY L, Meuwly JY, Sarivalasis A, Achtari C, et al
    Survival of the fetus: cervical cancer and pregnancy, a challenging combination.
    Lancet. 2020;396:725.

    August 2020
  5. CARDENAS-DE LA GARZA JA, Esquivel-Valerio JA, Arvizu-Rivera RI, Colunga-Pedraza PR, et al
    Flushing out a plasmacytoma in a patient with POEMS and AESOP syndromes.
    Lancet. 2020;396:e21.

    July 2020
  6. CAMPBELL BCV, Khatri P
    Lancet. 2020;396:129-142.
    PubMed     Abstract available

    June 2020
  7. FORTEA J, Vilaplana E, Carmona-Iragui M, Benejam B, et al
    Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Lancet. 2020;395:1988-1997.
    PubMed     Abstract available

    April 2020
  8. GOUJARD C, Salenave S, Briot K, Chanson P, et al
    Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns.
    Lancet. 2020;395:1304.

    March 2020
  9. MOORE C
    Prostate-specific membrane antigen PET-CT before radical treatment.
    Lancet. 2020 Mar 20. pii: S0140-6736(20)30527.

  10. HOFMAN MS, Lawrentschuk N, Francis RJ, Tang C, et al
    Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study.
    Lancet. 2020 Mar 20. pii: S0140-6736(20)30314.
    PubMed     Abstract available

    May 2019
  11. CAMPBELL BCV, Ma H, Ringleb PA, Parsons MW, et al
    Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Lancet. 2019 May 21. pii: S0140-6736(19)31053.
    PubMed     Abstract available

    March 2019
  12. OLMEDO-RENEAUM A, Garcia-Juarez I, Toapanta-Yanchapaxi L, De La Pena-Lopez R, et al
    Rogue "stem cell clinic" leads to Mycobacterium abscessus infection.
    Lancet. 2019;393:918.

    January 2019
  13. POWER SP, O'Mahony D
    Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
    Lancet. 2019;393:349.

    October 2017
    Continued conundrum of PET-CT and Hodgkin's lymphoma.
    Lancet. 2017 Oct 20. pii: S0140-6736(17)32343.

  15. BORCHMANN P, Goergen H, Kobe C, Lohri A, et al
    PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
    Lancet. 2017 Oct 20. pii: S0140-6736(17)32134.
    PubMed     Abstract available

    January 2017
  16. TAWAKOL A, Ishai A, Takx RA, Figueroa AL, et al
    Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)31714.
    PubMed     Abstract available

    June 2016
  17. DI NISIO M, van Es N, Buller HR
    Deep vein thrombosis and pulmonary embolism.
    Lancet. 2016 Jun 30. pii: S0140-6736(16)30514.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.